Promising drug cocktail aims to shrink aggressive nasal tumors before surgery
NCT ID NCT07616141
First seen Jun 03, 2026 · Last updated Jun 23, 2026 · Updated 7 times
Summary
This study tests whether giving a combination of anlotinib (a targeted therapy) and epirubicin (chemotherapy) before surgery can improve outcomes for people with advanced sinonasal adenoid cystic carcinoma, a rare and aggressive cancer of the nasal cavity and sinuses. About 76 participants will receive two cycles of the drugs, then undergo surgery and radiation. The main goal is to see if this approach increases the 3-year survival without cancer progression compared to historical rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, 200031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib (a targeted therapy) plus epirubicin (a chemotherapy drug)
What this could lead to
If successful, this drug combination before surgery could become a new standard treatment for advanced sinonasal adenoid cystic carcinoma, potentially improving survival and reducing the need for disfiguring surgeries.
What could go wrong
This is an early phase II trial with only 76 participants and no comparison group. The combination may cause side effects like fatigue, bleeding, or heart problems, and may not improve outcomes over current treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.